Philips Q1 2026 Results Beat Estimates

Royal Philips (PHG) reported stronger commercial momentum and margin expansion in its Q1 2026 results, released May 6, 2026, beating analyst expectations. The company reiterated its full-year 2026 outlook despite tariffs and cost inflation.

Quarterly Results and Segment Performance

Comparable order intake grew 6.0% in the quarter, led by the Diagnosis & Treatment and Connected Care segments and driven by demand in North America and international markets. Comparable group sales rose 4.0% to EUR 3.9 billion, while nominal sales declined due to foreign-exchange effects. Adjusted EBITA, a proxy for operating profit, reached EUR 353 million, lifting the adjusted EBITA margin 40 basis points to 9.0%. Sales gains, gross-margin improvement, and productivity savings offset tariffs and inflationary costs.

By segment, Diagnosis & Treatment posted 2.0% comparable sales growth with an adjusted EBITA margin of 9.8%, up 30 basis points. Connected Care recorded 3.0% comparable sales but saw its margin decline 60 basis points to 2.9%. Personal Health led growth with 9.0% comparable sales and a margin increase of 60 basis points to 15.8%.

Income from operations rose EUR 87 million year-over-year to EUR 241 million. The quarter included EUR 61 million in restructuring charges and EUR 34 million in Respironics-related charges, partly offset by a EUR 42 million release of an acquisition provision. CEO Roy Jakobs said the results reflected “disciplined execution against our plan in an uncertain macro-environment.”

Cash Flow, Productivity, and Outlook

Operating cash flow was EUR 188 million, with free cash flow of EUR 28 million. Philips achieved EUR 126 million in productivity savings during the quarter and remains on track to meet its EUR 1.5 billion target under the 2026–2028 productivity program.

The company reiterated its full-year 2026 guidance for comparable sales growth of 3.0%–4.5% and an adjusted EBITA margin target of 12.5%–13.0%. It also reaffirmed a free cash flow range of EUR 1.3–1.5 billion. This outlook accounts for known tariffs and cost inflation but excludes potential refunds from International Emergency Economic Powers Act tariffs and ongoing Philips Respironics-related proceedings, including a U.S. Department of Justice investigation.

On the post-earnings call, Jakobs said Philips plans to deploy artificial intelligence more aggressively for cost management and will adjust pricing to address inflationary pressures linked to tensions in the Middle East.

The quarter’s order intake growth, margin expansion, and early cash flow supported management’s decision to maintain guidance while managing tariff headwinds and Respironics-related legal matters.